Company Overview and News

13
Cellectar Announces 1-for-10 Reverse Stock Split

2018-07-13 globenewswire
MADISON, Wis., July 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces a 1-for-10 reverse split of its common stock, effective at the close of business today.
CLRB CLRBZ CLRBW

12
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma

2018-07-09 globenewswire
MADISON, Wis., July 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of Ewing’s sarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

57
Cue Biopharma Strengthens Board of Directors with Addition of Fred Driscoll to Chair Audit Committee

2018-06-28 globenewswire
CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today the addition of Fred Driscoll to the Company’s Board of Directors. Mr. Driscoll is an industry leader with more than 20 years of experience providing financial management and guidance for corporate development and shareholder value creation within the life sciences industry.
CYNA FLXN CLRB CUE MEIP CLRBZ CLRBW

17
Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial

2018-06-28 globenewswire
MADISON, Wis., June 28, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announces that the company will expand patient enrollment in the diffuse large b-cell lymphoma (DLBCL) cohort of its currently enrolling Phase 2 clinical trial of CLR 131.
CLRB CLRBZ CLRBW

89
Your Daily Pharma Scoop: Secondary Offering Review, Week Of June 8-15, VSTM, SRRA

2018-06-19 seekingalpha
Welcome to another week of secondary offering review. Like we have said before, secondary offerings are often a good time to enter into a stock. If a company has otherwise solid credentials but goes down on the offering, that's a good entry point, other things being constant.
GTHX CGEN KTWO VSTM ALPN CLRBZ HTGX CLRBW HTGY HTGZ HTGC CLRB SRRA

244
Your Daily Pharma Scoop: Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips

2018-06-11 seekingalpha
Aduro Biotech Inc. (ADRO) is a smallcap with a market capitalization of $533.397M. The company develops immunotherapy drugs, focuses on development of therapies that treat challenging diseases. The Berkeley, CA based company was founded as Oncologic, Inc. in 2000 and renamed to Aduro BioTech, Inc. in June 2008.
MNKD SCD IRWD CMRX TRXC K CLRBZ CLRBW OPHT ADRO FGEN JNJ IOVA LPCN CLRB PFE BMY

91
Your Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar Zooms

2018-06-11 seekingalpha
Scynexis (NASDAQ:SCYX) is a drug manufacturer focusing on infectious diseases and has $83.85M in market capitalization. The company’s lead candidate SCY-078 is on trial for treatment of multiple serious fungal infections. Some of these fungal infections like Acute Vulvovaginal Candidiasis, Invasive Candidiasis and Invasive Aspergillosis Combo are difficult to treat and can turn into life-threatening conditions.
REGN MYO GSK ZTS CLRB GSK CLRBZ PRPO CLRBW PTI SCYX

17
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma

2018-06-06 globenewswire
MADISON, Wis., June 06, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

18
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

2018-05-09 globenewswire
MADISON, Wis., May 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

17
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broad Range of Tumor Cells

2018-04-16 globenewswire
MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today the presentation of a late breaker poster entitled “Phospholipid drug conjugates (PDC™) show specificity for a broad range of tumor cells and provides a novel approach for targeted or precision therapy” at the American Association for Cancer Research (AACR) Annual Meeting underway in Chicago.
CLRB CLRBZ CLRBW

17
Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar’s CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting

2018-04-16 globenewswire
MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces the presentation of CLR 131 preclinical data in a poster discussion entitled “Therapeutic Combination of Radiolabeled CLR1404 with External Beam Radiation in Head and Neck Cancer Murine Xenograft Models” at the American Association for Cancer Research (AACR) Annual Meeting underway in Chicago.
CLRB CLRBZ CLRBW

64
Cerecor Appoints Simon Pedder to its Board of Directors

2018-04-09 marketwired
BALTIMORE, MD--(Marketwired - April 09, 2018) - Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors.
CERC ATNX CLRB CLRBZ CLRBW

54
Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer

2018-04-04 globenewswire
MADISON, Wis., April 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announces the appointment of Brian M. Posner as chief financial officer, effective as of April 1, 2018.
LGNZZ LGNYZ LGND LGNXZ CLRB LGNDZ CLRBZ CLRBW OPTT

17
Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma

2018-04-03 globenewswire
MADISON, Wis., April 03, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. P150207US03, entitled “Alkylphosphocholine analogs for multiple myeloma imaging and therapy.
CLRB CLRBZ CLRBW

17
Cellectar Biosciences' (CLRB) CEO Jim Caruso on Q4 2017 Results - Earnings Call Transcript

2018-03-22 seekingalpha
Welcome to the Cellectar Biosciences 2017 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we’ll hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded March 22, 2018.
CLRB CLRBZ CLRBW

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

4h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

CUSIP: 15117F112